Recruiting Ulcerative Colitis Studies in San Francisco
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately...
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will comp...
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients w...
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC)....
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years ...
About Ulcerative Colitis Clinical Trials in San Francisco
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the colon and rectum. It typically presents with bloody diarrhea, abdominal pain, and urgency. Treatment includes aminosalicylates, corticosteroids, immunosuppressants, and biologics.
There are currently 6 ulcerative colitis clinical trials recruiting participants in San Francisco, CALIFORNIA. These studies are seeking a combined 942 participants. Research is being sponsored by Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ulcerative Colitis Clinical Trials in San Francisco — FAQ
Are there ulcerative colitis clinical trials in San Francisco?
Yes, there are 6 ulcerative colitis clinical trials currently recruiting in San Francisco, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Francisco?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.
Are clinical trials in San Francisco free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.
What ulcerative colitis treatments are being tested?
The 6 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for ulcerative colitis.
Data updated March 2, 2026 from ClinicalTrials.gov